Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06375512
Other study ID # IN001001
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date July 2024
Est. completion date June 2026

Study information

Verified date April 2024
Source Shenzhen Shenxin Biotechnology Co., Ltd
Contact Clinical Development Innorna
Phone +86-755-86532375
Email cd@innorna.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date June 2026
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 69 Years
Eligibility Key Inclusion Criteria: 1. Healthy male or female participants aged between 50 to 69 years of age, inclusive. 2. Body weight = 50 kg for males and = 45 kg for females and body mass index (BMI) in the range of 18.5 to 35 kg/m^2. 3. Participants with asymptomatic medical conditions (eg, hypertension, dyslipidemia) that are not associated with end-organ damage may be included provided they are being appropriately treated as per standard of care, are clinically stable, and are not receiving treatments that would be exclusionary in the opinion of the Investigator. 4. For all women of childbearing potential (WOCBP) females must be non-pregnant and non-lactating and must use a highly effective contraceptive method from at least 30 days prior to enrollment through to 6 months after second vaccination. 5. Willing to provide documented informed consent and comply with the requirements of the clinical study protocol. Key Exclusion Criteria: 1. Participants with a known history of HZ. 2. Participants with a known history of GBS, encephalomyelitis, or transverse myelitis. 3. Participants with a known history of heart disease (eg, heart failure, recent coronary artery disease, myocarditis, pericarditis, or cardiomyopathy). 4. Participants with acute medical illness or febrile illness, including oral temperature = 38.0°C (= 100.4°F) within 1 day prior to screening. Participants with suspected or confirmed COVID-19 should be excluded and referred for medical care. 5. Participants with any medical, neurological, or psychiatric condition that, in the opinion of the Investigator, could place the participant at an unacceptable risk of injury or render the participant unable to comply with all study procedures and achieve successful completion of the trial. 6. Participants with a known history of hypersensitivity reactions including anaphylaxis and urticaria, or other significant adverse reactions to IN001 or its excipients; or participants with a known history of severe allergic reaction (eg, anaphylaxis) to any component of SHINGRIX™ or after a previous dose of SHINGRIX™. 7. Participants who have a positive pregnancy test at the screening visit or who intend to become pregnant during or breastfeed through Study Day 236 (6 months after second vaccination). 8. Participants with uncontrolled hypertension (supine systolic blood pressure = 140 mmHg or supine average diastolic blood pressure = 90 mmHg at screening). 9. Participants with a history of significant hematologic abnormalities or history of thrombosis with thrombocytopenia syndrome. 10. Participants with hematology and/or clinical chemistry laboratory result(s) that meet the definition of a Grade = 2 abnormality as delineated in the FDA guidance. 11. Participants with a history of congenital or acquired immunodeficiency. 12. Participants with an immunosuppressive or immunodeficient state, asplenia, or recurrent severe infections. 13. Participants with a known history of chronic infection including, but not limited to, human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and active tuberculosis. 14. Positive HBV and HCV panel and/or positive HIV test. 15. Participants with positive syphilis test. 16. Participants with chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial participation or interpretation of study results. 17. Participants with a known history of vaccination against varicella or HZ. 18. Participants who have received immunoglobulins and/or any blood or blood products within 4 months before the first study vaccination or who plan to receive such products at any time during the study. 19. Participants who have received immunomodulatory, immunostimulatory, or immunosuppressant drugs including interferon and cytotoxic drugs within 3 months of screening (or 5 half-lives, whichever is longer) or who plan to receive them across the duration of the study. 20. Participants requiring systemic corticosteroids exceeding 10 mg/day of prednisone equivalent for = 10 days within 30 days of screening. The use of topical, ophthalmic, inhaled, and intranasal steroid preparations will be permitted. 21. Participants who have received or plan to receive any licensed vaccine = 28 days prior to the first vaccination (Day 0) or who plan to receive a licensed vaccine = 28 days after the first study vaccination or = 28 days before or after the second study vaccination. The only exception is licensed inactivated influenza vaccine or non-replicating influenza vaccine, which may be given = 14 days before or = 28 days after receipt the first or second study vaccination. 22. Participants receiving treatment with another investigational drug, biological agent, or device = 28 days of screening, or 5 half-lives of the investigational drug, whichever is longer; or currently enrolled in or plans to participate in another clinical trial with an investigational agent during the study period (including the follow-up period of the study). 23. Participants with history of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening. 24. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week. 25. Positive alcohol breath test result or positive urine drug screen at screening and Study Day 0. 26. Participants who are Investigator site staff members, employees of the Sponsor or the clinical research organization directly involved in the conduct of the study, or site staff members otherwise supervised by the Investigator or immediate family members of any of the previously mentioned individuals. 27. Participants with a demonstrated inability to comply with the study procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
HZ Vaccine (IN001)
Formulation for injection
Placebo
0.9% sodium chloride (normal saline) for injection
Shingrix
Sterile suspension for injection

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen Shenxin Biotechnology Co., Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Reporting Solicited Local Reactions For 14 days after each vaccination
Primary Percentage of Participants Reporting Solicited Systemic Reactions For 14 days after each vaccination
Primary Percentage of Participants With Unsolicited Adverse Events (AEs) For 28 days after each vaccination
Primary Percentage of Participants With Any Medically Attended AEs (MAAEs) From initial vaccination to 6 months after the second vaccination
Primary Percentage of Participants With Any Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), AEs Leading to Vaccine Discontinuation, and AEs Leading to Study Withdrawal From initial vaccination to 12 months after the second vaccination
Secondary Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) Baseline (before first vaccination); 28 and 56 days post-first vaccination; 14 and 28 days and 3, 6 and 12 months post-second vaccination
Secondary Change from Baseline in Geometric Mean Fold Rise (GMFR) of Anti-gE Antibodies as Measured by ELISA 28 and 56 days post-first vaccination; 14 and 28 days and 3, 6 and 12 months post-second vaccination
Secondary Proportion of Participants with Vaccine Response in Anti-gE Antibodies as Measured by ELISA 28 and 56 days post-first vaccination; 14 and 28 days and 3, 6 and 12 months post-second vaccination
Secondary Geometric Mean Titer (GMT) of Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay baseline (before first vaccination); 56 days post-first vaccination; 28 days and 6 and 12 months post-second vaccination
Secondary Change from Baseline in GMFR of Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay 56 days post-first vaccination; 28 days and 6 and 12 months post-second vaccination
Secondary Proportion of Participants with Vaccine Response in Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay 56 days post-first vaccination; 28 days and 6 and 12 months post-second vaccination
Secondary gE-specific T Cell Response (IFN-? and IL-4 Secreting T Cells) as Measured by Enzyme-Linked Immunospot (ELISpot) Baseline (before first vaccination); 28 and 56 days post-first vaccination; 28 days and 3, 6 and 12 months post-second vaccination
Secondary Frequencies of gE-specific CD4+ and CD8+ T Cells Expressing Activation Markers (i.e., IFN-?, IL-2, TNFa, CD40L) as Measured by Intracellular Cytokine Staining (ICS) Baseline (before first vaccination); 56 days post-first vaccination; 14 and 28 days post-second vaccination
See also
  Status Clinical Trial Phase
Completed NCT03120364 - Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over Phase 3
Completed NCT01165203 - Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects Phase 2
Recruiting NCT06088745 - A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine Phase 3
Completed NCT01385566 - A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) Phase 1
Completed NCT01911065 - T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Phase 4
Completed NCT01137669 - ZOSTAVAX® in Renal Transplant Patients Phase 1
Completed NCT00550745 - ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Phase 4
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT00231816 - A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011) Phase 3
Completed NCT02852876 - Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food Phase 1
Completed NCT05082688 - Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) Phase 2
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Active, not recruiting NCT04091451 - A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles Phase 3
Completed NCT02519855 - Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) Phase 3
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Completed NCT05047770 - A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine Phase 3
Completed NCT03314103 - Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age Phase 3
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT01954251 - Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older Phase 3